Bradley Nixon Scharfe Sells 1,000,000 Shares of Charles River Laboratories International, Inc. (CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00.

Bradley Nixon Scharfe also recently made the following trade(s):

  • On Monday, October 30th, Bradley Nixon Scharfe bought 2,500 shares of Charles River Laboratories International stock. The stock was bought at an average price of $0.25 per share, for a total transaction of $625.00.
  • On Wednesday, October 25th, Bradley Nixon Scharfe bought 3,000 shares of Charles River Laboratories International stock. The stock was bought at an average price of $0.27 per share, for a total transaction of $810.00.
  • On Thursday, October 19th, Bradley Nixon Scharfe bought 2,000 shares of Charles River Laboratories International stock. The stock was bought at an average price of $0.29 per share, for a total transaction of $580.00.
  • On Tuesday, October 17th, Bradley Nixon Scharfe bought 3,000 shares of Charles River Laboratories International stock. The stock was bought at an average price of $0.29 per share, for a total transaction of $870.00.

Shares of Charles River Laboratories International, Inc. (CRL) opened at $100.92 on Wednesday. The company has a market capitalization of $4,827.56, a price-to-earnings ratio of 20.03, a P/E/G ratio of 1.63 and a beta of 0.94. Charles River Laboratories International, Inc. has a fifty-two week low of $69.51 and a fifty-two week high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same period last year, the business posted $1.18 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. analysts anticipate that Charles River Laboratories International, Inc. will post 5.13 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/11/15/bradley-nixon-scharfe-sells-1000000-shares-of-charles-river-laboratories-international-inc-crl-stock.html.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Charles River Laboratories International by 0.5% in the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock worth $511,893,000 after buying an additional 27,217 shares during the last quarter. BlackRock Inc. increased its position in Charles River Laboratories International by 4.6% in the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after buying an additional 177,239 shares during the last quarter. FMR LLC increased its position in Charles River Laboratories International by 23.8% in the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after buying an additional 591,066 shares during the last quarter. State Street Corp increased its position in Charles River Laboratories International by 2.3% in the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after buying an additional 28,365 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Charles River Laboratories International by 14.4% in the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock worth $123,391,000 after buying an additional 153,374 shares during the last quarter. 97.46% of the stock is owned by institutional investors and hedge funds.

CRL has been the topic of a number of recent research reports. Credit Suisse Group restated a “neutral” rating and issued a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a report on Monday, October 16th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a report on Tuesday, October 24th. Jefferies Group LLC restated a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price on the stock. Finally, ValuEngine lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $106.05.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply